Objectives: This study
aimed to assess the interim outcomes for drug-resistant tuberculosis (DR-TB) patients treated with bedaquiline regimen under the
operational research conditions compared to DR-TB patients treated without
bedaquiline in their regimen, and to describe the adverse events that occurred
among patients treated with bedaquiline in the Philippines.Design: Patients who were treated with a bedaquiline-containing regimen from
June 2016 to May 2017 were included in this study as the intervention group,
while patients who were treated without bedaquiline regimen from January 2013
to May 2016 were included as the comparison group. The interim treatment
outcomes were compared using Chi-square test. The analysis of time to culture
conversion within 6 months of treatment was conducted. A Cox proportional
hazard model was constructed to identify the variables associated with a
favorable interim treatment outcome. The R program was used for statistical
analysis.Results: On the 6th month of treatment, the culture conversion for patients
treated with a bedaquiline-containing regimen was
References
[1]
Department of Health-National TB Control Program (2018) National Tuberculosis Prevalence Survey 2016 Philippines. Department of Health-Disease Prevention and Control Bureau, Manila.
[2]
World Health Organization (2018) Global Tuberculosis Report 2018. WHO/CDS/TB/2018.20, World Health Organization, Geneva.
[3]
Department of Health-National TB Control Program (2016) Second National Drug Resistance Survey on Tuberculosis in the Philippines, Technical Report 2014. Department of Health-Disease Prevention and Control Bureau, Manila.
[4]
Department of Health-National TB Control Program (2016) NTP Cohort Analysis. Department of Health-Disease Prevention and Control Bureau, Manila.
[5]
World Health Organization (2013) The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. WHO/HTM/TB/2013.6, World Health Organization, Geneva.
[6]
Gras, J. (2013) Bedaquiline for the Treatment of Pulmonary, Multidrug-Resistant Tuberculosis in Adults. Drugs Today, 29, 353-361.
[7]
World Health Organization (2013) Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, Emergency Update 2008. WHO/HTM/TB/2008.402, World Health Organization, Geneva.
[8]
Guglielmetti, L. Le Du, D., Jachym, M., Benoit, H., Martin, D., Caumes, E., et al. (2015) Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort. Clinical Infectious Diseases, 60, 188-194. https://doi.org/10.1093/cid/ciu786
[9]
National Cancer Institute (2010) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. NIH Publication.
[10]
World Health Organization (2015) Active Tuberculosis Drug-Safety Monitoring and Management (ADSM): Framework for Implementation. WHO/HTM/TB/2015.28, World Health Organization, Geneva.
[11]
Diacon, A., Pym, A., Grobusch, M.P., De Los Rios, J.M., Gotuzzo, E., Vasilyeva, I., et al. (2014) Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. New England Journal of Medicine, 371, 723-732. https://doi.org/10.1056/NEJMoa1313865
[12]
Hewison, C., Bastard, M., Khachatryan, N., Kotrikadze, T., Hayrapetyan, A., Avaliani, Z., et al. (2018) Is 6 Months of Bedaquiline Enough? Results from the Compassionate Use of Bedaquiline in Armenia and Georgia. International Journal of Tuberculosis Lung Diseases, 22, 766-772. https://doi.org/10.5588/ijtld.17.0840
[13]
Mbuagbaw, L. Guglielmetti, L., Hewison, C., Bakare, N., Bastard, M., Caumes, E., et al. (2019) Outcome of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerging Infectious Diseases, 5, 936-943. https://doi.org/10.3201/eid2505.181823
[14]
Borisov, S.E., Dheda, K., Enwerem M., Leyet, R.R., D’Ambrosio, L., Centis, R., et al. (2017) Effectiveness and Safety of Bedaquiline-Containing Regimens in the Treatment of MDR- and XDR-TB: A Multicentre Study. European Respiratory Journal, 49, Article ID: 1700387. https://doi.org/10.1183/13993003.00387-2017
[15]
Guglielmetti, L., Jaspard, M., Le Du, D., Lachatre, M., Marigot-Outtandy, D., Bernard, C., et al. (2017) Long-Term Outcome and Safety Prolonged Bedaquiline Treatment for Multidrug-Resistant Tuberculosis. European Respiratory Journal, 49, Article ID 1601799. https://doi.org/10.1183/13993003.01799-2016
[16]
The endTB Project (2016) EndTB Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.3. Partners in Health, Boston.
[17]
Owens, R.C. and Nolin, T.D. (2006) Antimicrobial-Associated QT Interval Prolongation: Pointers of Interest. Clinical Infectious Diseases, 3, 1603-1611. https://doi.org/10.1086/508873
[18]
Department of Health-National TB Control Program (2015) NTP Cohort Analysis. Department of Health-Disease Prevention and Control Bureau, Manila.
